Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment

AIMS: Fluocinolone acetonide (FAc) is an intravitreal corticosteroid implant approved for the second-line treatment of diabetic macular edema (DME). This study compared outcomes of patients with DME switched directly to an FAc implant, versus indirectly via dexamethasone, after anti-VEGF therapy fai...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Acta Diabetol
Autores principales: Rehak, Matus, Busch, Catharina, Unterlauft, Jan-Darius, Jochmann, Claudia, Wiedemann, Peter
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer Milan 2019
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7093402/
https://ncbi.nlm.nih.gov/pubmed/31749051
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00592-019-01439-x
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares